Haz tu predicción
Comprar enPago
$100
$178
Compra predicción

Acerca de

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2030, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2030, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2030. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2030, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2030, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2030, the market will resolve to No immediately.

If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2030, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do NOT constitute approvals: Complete Response Letters (CRLs) indicating the application cannot be approved in its current form Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Emergency Use Authorization (EUA) without full approval Approval only for export or for use outside the United States If the FDA issues a Complete Response Letter before Jan 1, 2030, the market will resolve to No unless the FDA subsequently approves midomafetamine / MDMA for PTSD after addressing the CRL concerns and before Jan 1, 2030. If the FDA convenes an Advisory Committee that votes against approval but the FDA approves midomafetamine / MDMA for PTSD anyway before Jan 1, 2030, the market will resolve to Yes. If midomafetamine / MDMA for PTSD receives accelerated approval that is later withdrawn before Jan 1, 2030, the market will resolve based on whether the initial accelerated approval occurred after Issuance (Yes), regardless of the subsequent withdrawal. If the drug sponsor withdraws the application before FDA action and before Jan 1, 2030, the market will resolve to No immediately.

Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading
Loading

Estadísticas clave

Vencimiento
1 ene 2030(1139 días)
Interés
6668,34 US$
Total
14 mil US$

Detalles

Cronograma y reglas

Calendarios y pagos

Este mercado se cerrará y expirará cuando ocurra un resultado. De lo contrario, se cierra para el 1 ene 2030, 4:59 a. m. GMT+0.

Prohibiciones de operación

Las siguientes entidades tienen prohibido realizar la operación de este contrato:
Mercados en tendencia

Una nueva era de Coinbase ha comenzado

El futuro del dinero está aquí. Sé uno de los primeros en obtener acceso y probar nuevas funciones en cuanto estén disponibles.

Crea una cuenta ahora
FAQ

Saber más

Información legal
Coinbase Financial Markets ofrece los mercados de predicción, un comercio de contratos registrado ante la Commodity Futures Trading Commission y miembro de National Futures Association. La operación de contratos de predicción representa un riesgo considerable y puede causar la pérdida de toda tu inversión. Los contratos se pagan solo si ocurre el evento especificado. Opera solo si comprendes el producto y crees que es apropiado para tu situación financiera y tus objetivos.Parte del contenido de las noticias fue preparado por terceros que no están afiliados a Coinbase Financial Markets ni a ninguno de sus afiliados, y Coinbase no se responsabiliza por dicho contenido. Coinbase no es responsable por errores o demoras en el contenido, o por las acciones tomadas en virtud del contenido. La información es solo para fines informativos, no es un asesoramiento de inversión. Esta no es una recomendación para comprar o vender un activo específico ni para aplicar determinada estrategia de inversión. Coinbase no hace ninguna declaración sobre la precisión, la idoneidad o la validez de la información proporcionada o de un activo específico. Los precios que se muestran son solo con fines ilustrativos. Los precios reales de las criptomonedas y las estadísticas asociadas con ellas pueden variar. Los datos presentados pueden reflejar los activos que se comercializan en la casa de cambio Coinbase y en casas de cambio de criptomonedas seleccionadas. El rendimiento pasado no es un indicador confiable de resultados futuros.